Are you up to date on the key clinical data for available immuno-oncologic agents in advanced endometrial and cervical cancers?
This educational series examines the significance and potential impact of immunotherapy and antibody-drug conjugates in patients with advanced endometrial and cervical cancers. Our global experts discuss key clinical data from first- and second-line treatment, management considerations during immuno-oncologic therapy, and more!
Provided by:
In Partnership with:
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer
Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer